文献速递结核与非结核分枝杆菌

项目场景中12周每周一次异烟肼联合利福喷丁治疗潜伏性结核感染的高完成率

High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该观察性队列研究通过美国16个项目评估潜伏性结核感染患者接受12周每周一次直接观察异烟肼联合利福喷丁(3HP)方案的完成率、不良反应及停药相关因素。3288例符合完成3HP条件的患者中2867例(87.2%)完成治疗;儿童完成率最高(94.5%),无家可归者完成率81.2%。结论认为常规医疗场景中3HP完成率高于临床试验报告及其他方案历史数据。

要点

  • 3HP方案在常规医疗场景完成率达87.2%,高于临床试验报告的82%。
  • 2-17岁儿童完成率最高(94.5%),无家可归者完成率81.2%。
  • 羁押和无家可归与停药风险升高独立相关(ARR分别为1.43和1.72)。

核心结论

  • 常规医疗场景中3HP方案总体完成率高于临床试验报告,也高于其他方案在报告依从性差人群中的历史观察数据。
  • 广泛使用3HP治疗潜伏性结核感染可能加速美国结核病消除。

研究设计与样本

  • 观察性队列研究,通过美国16个项目纳入接受3HP方案的潜伏性结核感染患者。
  • 评估治疗完成、药物不良反应及治疗中断相关因素。

主要发现

  • 3288例符合完成3HP条件的患者中,2867例(87.2%)完成治疗。
  • 2-17岁儿童完成率最高,为94.5%(155/164)。
  • 报告无家可归的患者完成率为81.2%(147/181)。

临床怎么用

  • 在常规医疗项目中可推广3HP方案用于潜伏性结核感染治疗,并关注羁押及无家可归人群的依从性支持。
  • 儿童和结核病患者接触者完成率较高,可优先推荐3HP。
  • 需监测药物不良反应,但多数报告不良反应者仍可完成治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings. METHODS: Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation. RESULTS: Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2-17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23-.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25-2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52-.89]; P = .005) and students (ARR, 0.45 [95% CI, .21-.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08-1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25-2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment. CONCLUSIONS: Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sandul AL, Nwana N, Holcombe JM, et al. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. Clin Infect Dis. 2017. PMID: 28575208. doi:10.1093/cid/cix505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。